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dorzolamide (P < 0.01). Seventy-ﬁve percent of the
patients had a treatment duration longer than 203 days
when treated with brinzolamide versus 140 days with
dorzolamide. The probability of a failure was 1.61 (P <
0.02) times higher with dorzolamide, after adjusting for
treatment line and the number of drugs prescribed. The
yearly glaucoma treatment cost for a patient with a treat-
ment failure was found to be higher (GBP 15.21) than for
patients who continued their treatment. CONCLUSION:
In comparison to dorzolamide, patients treated with brin-
zolamide experienced fewer treatment failures, leading to
cost savings.
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OBJECTIVES: The purpose of this study was to com-
pare the intraocular pressure (IOP)—lowering efﬁcacy
and cost-effectiveness of Lumigan (Bimatoprost) 
versus Xalatan (Latanoprost) in glaucoma patients.
METHODS: A Markov model was developed to compare
the cost-effectiveness of Lumigan initiated treatment with
Xalatan initiated treatment in the context of the French
Health care system. The model uses a timeframe of one
year and data from published randomised clinical trials,
which included a total of 249 patients. Patients were
allowed to switch medication up to a maximum of two
times if target IOP was not met or adverse events occurred
and each switch was associated with a physician visit
(cost: €23.00 each). Drug costs used were €20.10 for
Lumigan and €17.67 for Xalatan. A probabilistic analy-
sis was performed using 1000 Monte Carlo simulations.
The primary outcome measures were the number of
months patients spent at IOP < 17mmHg and the cost
per month at IOP < 17mmHg. Sensitivity analyses were
conducted varying the target IOPs. RESULTS: More
patient months at IOP < 17mmHg were achieved by
patients on Lumigan versus Xalatan initiated therapy (9.7
versus 9.3; P < 0.05). Lumigan initiated therapy was also
associated with fewer annual physician visits per patient
(5.14 compared to 5.48; P < 0.001). The cost per patient
per month at IOP < 17mmHg was €41.96 for patients on
Lumigan compared to €44.60 for those on a Xalatan ini-
tiated therapy. The results of the sensitivity analysis deter-
mined that at target IOPs of 14 to 17mmHg there was a
lower average annual treatment cost per patient for
Lumigan initiated patients. CONCLUSIONS: Lumigan
initiated treatment is more cost-effective than Xalatan ini-
tiated treatment at target IOPs between 14–17mmHg.
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OBJECTIVE: The aim of glaucoma treatment is to delay
progression of the disease to blindness, by lowering 
intra-ocular pressure (IOP). Clinical trials have shown
that latanoprost (Xalatan®, Pﬁzer) achieves better IOP
control than beta-blockers. We assessed the cost-
effectiveness of latanoprost as 1st-line therapy, compared
to beta-blockers, in Austria, Belgium, France, Germany,
Italy and the UK. METHODS: Clinical outcomes and
resource utilisation data were obtained from a retrospec-
tive chart review study of glaucoma patients initially
treated with latanoprost or beta-blocker in Germany,
Italy, Spain, and the UK. A Markov model was used to
calculate the number of months of IOP control and total
costs (including drugs, physician visits, diagnostic tests
and surgeries) per patient over 2 years from a third-party
payer perspective. The model was estimated by Monte
Carlo simulation. The incremental cost per IOP-
controlled month was reported for each country and 
variability around this ratio was examined. RESULTS:
Seventy-three percent of patients remained on treatment
with latanoprost, compared to 29% with beta-blocker,
over 2 years. The higher acquisition cost of latanoprost
was partly offset by lower surgery costs. The ICER ranged
from €24.94 (95% CI: 20.68–30.11) per IOP-controlled
month, for France, to €272.84 (251.24–297.17), for
Germany. Sensitivity analyses showed that survival on
therapy, the duration of medication bottles and parame-
ters related to surgery costs were the main drivers of 
cost-effectiveness. CONCLUSIONS: Differences between
countries were mainly attributable to variation in drug
and surgery unit costs. First-line treatment with
latanoprost is predicted to be cost-effective if decision-
makers value the control of IOP at a minimum of approx-
imately €25 per month in France, €45 per month in
Belgium, UK and €275 per month in Germany, under the
current system and costs of care. Relatively low unit costs
for surgery and the drug co-payment system contributed
to the higher ICER in Germany.
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